Interpretation of expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples(2024)
Multiple myeloma(MM)is the second most common hematologic malignant tumor.Standard of care and new drug-based regimens have greatly improved the survival of MM patients,but minimal residual dis-ease(MRD)causes relapse in the vast majority of patients.At present,next-generation flow cytometry(NGF)and next-generation sequencing(NGS)are the mainstream technologies for detecting MRD based on bone marrow sam-ples.To standardize and normalize MRD detection,the Experimental Diagnosis Group and Plasma Cell Disease Group of the Hematology Branch of the Chinese Medical Association,and the Multiple Myeloma Professional Committee of the Chinese Medical Doctor Association discussed and formulated the Chinese expert consensus on the application of NGF and NGS technology for MRD detection in MM patients.To better guide clinical practice,this article intends to interpret the clinical and laboratory parts of the consensus.
NETL
NSTL
万方数据
